Introduction
Methods
Study subjects
Statistical analysis
Results
General characteristics
Characteristic | Male (n = 76) | Female (n = 30) | p-value |
---|---|---|---|
Age—years—median (IQR) | 65 (53–74) | 65 (57–75) | 0.763 |
BMI—kg/m2—median (IQR) | 26.1 (24.5–29.0) | 25.7 (24.1–29.1) | 0.735 |
OHCA—no. (%) | 66 (86.8) | 24 (80.0) | 0.380 |
Initial rhythm—no. (%) | – | – | 0.272 |
Shockable | 59 (77.6) | 18 (60.0) | – |
Non-shockable | 16 (21.1) | 10 (33.3) | – |
Unknown | 1 (1.3) | 2 (6.7) | – |
Bystander CPR—no (%) | 44 (75.9) | 20 (100) | 0.02 |
Unknown | 18 (23.7) | 10 (33.3) | – |
Admission to TCC—no (%) | – | – | 0.651 |
Direct | 59 (77.6) | 24 (80.0) | – |
Interfacility | 12 (15.8) | 3 (10.0) | – |
Intrahospital TCC | 5 (6.6) | 3 (10.0) | – |
Transport modality—no (%) | – | – | 0.555 |
Airborne | 27 (35.5) | 13 (43.3) | – |
Ground transport | 44 (57.9) | 14 (46.7) | – |
Intrahospital | 5 (6.6) | 3 (10.0) | – |
Smoker—no (%) | 36 (47.4) | 14 (46.7) | 0.205 |
Comorbidities—no. (%) | – | – | – |
Arterial hypertension | 53 (69.7) | 18 (60.0) | 0.625 |
Diabetes mellitus | 14 (18.4) | 5 (16.7) | 0.776 |
Hyperlipidemia | 41 (53.9) | 16 (53.3) | 0.789 |
CKD | 15 (19.7) | 5 (16.7) | 0.758 |
COPD | 8 (10.5) | 5 (16.7) | 0.511 |
OSA | 6 (7.9) | 1 (3.3) | 0.670 |
History of CAD | 15 (19.7) | 3 (10.0) | 0.268 |
History of cardiac surgery | 7 (9.2) | 1 (3.3) | 0.432 |
Cause of cardiac arrest—no. (%) | – | – | 0.117 |
ACS | 46 (60.5) | 19 (63.3) | – |
Rhythmological | 18 (23.7) | 1 (3.3) | – |
Asphyxia/respiratory failure | 4 (5.3) | 4 (13.3) | – |
Pulmonary embolism | 3 (3.9) | 3 (10.0) | – |
Other | 5 (6.6) | 3 (10.0) | – |
SOFA score at admission—median (IQR) | 11 (9–12) | 11 (9–12) | 0.400 |
SAPS II at admission—median (IQR) | 78 (70.5–84.8) | 80.5 (75–85.8) | 0.269 |
Mechanical ventilation—no. (%) | 73 (96.1) | 27 (90.0) | 0.348 |
Duration of mechanical ventilation—h—median (IQR) | 48.5 (34–133) | 43 (24–143) | 0.636 |
Delirium—no (%) | 20 (26.3) | 4 (13.3) | 0.200 |
Vasopressor use—no. (%) | 70 (92.1) | 28 (93.3) | > 0.99 |
Targeted temperature management—no. (%) | 53 (69.7) | 20 (66.7) | 0.817 |
Continuous hemodiafiltration—no. (%) | 8 (10.5) | 2 (6.7) | 0.721 |
Antimicrobial therapy—no. (%) | 71 (93.4) | 27 (90.0) | 0.685 |
Systemic lysis—no. (%) | 6 (7.9) | 3 (10.0) | 0.710 |
Blood transfusion—no. (%) | 10 (13.2) | 3 (10.0) | 0.755 |
Coronary angiography—no. (%) | 60 (78.9) | 21 (70.0) | 0.324 |
PCI—no. (%) | 42 (55.3) | 17 (56.7) | > 0.99 |
Left ventricular ejection fraction—no. (%) | – | – | > 0.99 |
Normal | 11 (14.5) | 6 (20.0) | – |
Mildly abnormal | 17 (22.4) | 8 (26.7) | – |
Moderately abnormal | 27 (35.5) | 8 (26.7) | – |
Severely abnormal | 21 (27.6) | 8 (26.7) | – |
Lab value | Male | Female | p-value |
---|---|---|---|
pH-value at admission—median (IQR) | 7.210 (7.091–7.308) | 7.251 (6.995–7.363) | 0.543 |
Lactate at admission—mmol/L—median (IQR) | 2.6 (1.7–4.5) | 2.5 (1.6–5.0) | 0.822 |
Base excess at admission—mmol/L—median (IQR) | −8.0 (−13.6 to −5.3) | −9.4 (−14.0 to −5.3) | 0.797 |
Blood glucose at admission—mmol/L—median (IQR) | 8.9 (7.7–12) | 13 (10–16.1) | 0.001 |
Hemoglobin at admission—g/dL—median (IQR) | 14.3 (13.2–15.2) | 12.9 (12.3–13.5) | 0.001 |
Leucocyte count at admission—G/L—median (IQR) | 14.3 (10.6–17.8) | 14.8 (12.7–18.4) | 0.449 |
Thrombocyte count at admission—G/L—median (IQR) | 225 (187–273) | 273 (205–329) | 0.041 |
CRP at admission—mg/dL—median (IQR) | 0.3 (0.1–1.0) | 0.5 (0.3–1.6) | 0.080 |
Sodium at admission—mmol/L—median (IQR) | 139 (136–141) | 138 (136–139) | 0.229 |
Chloride at admission—mmol/L—median (IQR) | 100 (97–102) | 100 (98–101) | 0.688 |
Calcium at admission—mmol/L—median (IQR) | 2.2 (2.1–2.3) | 2.2 (2.2–2.3) | 0.278 |
Potassium at admission—mmol/L—median (IQR) | 4 (3.6–4.6) | 3.8 (3.6–4.3) | 0.343 |
Creatinine at admission—mg/dL—median (IQR) | 1.3 (1.1–1.4) | 1.1 (0.9–1.3) | 0.005 |
Urea at admission—mg/dL—median (IQR) | 39 (33–49) | 38 (31–45) | 0.410 |
AST—U/l—median (IQR) | 150 (93–258) | 253 (95–535) | 0.098 |
ALT—U/l—median (IQR) | 111 (63–219) | 166 (59–305) | 0.168 |
Bilirubin—mg/dL—median (IQR) | 0.5 (0.4–0.8) | 0.4 (0.3–0.6) | 0.048 |
GGT at admission—U/L—median (IQR) | 59 (41–106) | 44 (30–71) | 0.054 |
CHE—U/mL—median (IQR) | 5.9 (7.0–7.9) | 7.0 (6.5–8.4) | 0.502 |
Albumin—g/dL—median (IQR) | 3.5 (3.0–4.0) | 3.0 (3.0) | 0.683 |
Creatine kinase at admission—U/L—median (IQR) | 224 (147–614) | 192 (121–545) | 0.483 |
hsTroponin T—ng/L—median (IQR) | 148 (51–447) | 112 (47–708) | 0.720 |
HbA1c—mmol/mol—median (IQR) | 36.6 (34.4–41) | 37.7 (35.5–39.9) | 0.052 |
HbA1c not available—no (%) | 13 (17.1) | 10 (33.3) | – |
LDL—mg/dL—median (IQR) | 72 (51–106) | 77 (46–108) | 0.92 |
LDL not available—no (%) | 4 (5.3) | 1 (3.3) | – |
Outcome and survival analysis
Outcome | Male | Female | p-value |
---|---|---|---|
ICU length of stay—hr—median (IQR) | 128 (69–220) | 114 (51–235) | 0.594 |
Hospital length of stay—days median (IQR) | – | – | 0.168 |
Days—median (IQR) | 9 (5–20) | 7 (4–12) | – |
Transferred to other hospital—no. (%) | 15 (19.7) | 9 (30.0) | – |
Survival at 30 days—no (%) | 56 (73.7) | 18 (60.0) | 0.167 |
Survival at 6 months—no (%) | 51 (68.0) | 17 (56.7) | 0.272 |
Neurological outcome at 30 days—no (%) | – | – | 0.630 |
CPC 1 | 44 (78.6) | 13 (72.2) | – |
CPC 2 | 6 (10.7) | 2 (11.1) | – |
CPC 3 | 3 (5.4) | 2 (11.1) | – |
CPC 4 | 3 (5.4) | 1 (5.6) | – |
Neurological outcome at 6 months—no (%) | – | – | > 0.99 |
CPC 1 | 45 (88.2) | 15 (88.2) | – |
CPC 2 | 6 (11.8) | 2 (11.8) | – |